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Abstract 
Background: MicroRNAs (miRNAs) play important roles in cancer initiation and development. Epithelial–mesen-
chymal transition (EMT) is a form of cellular plasticity that is critical for embryonic development and metastasis. The 
purpose of the study was to determine the function and mechanism of miR-484 in initiation and development of 
cervical cancer (CC).
Methods: We determined the expression levels of miR-484 in cervical cancer tissues and cell lines with RT-qPCR. 
Prediction algorithms and EGFP reporter assay were performed to evaluate the targets for miR-484. MTT assay, colony 
formation assay, flow cytometric analysis, transwell cell migration and invasion assays, and detection of EMT markers 
were employed to investigate the roles of miR-484 and the targets in regulation of cell proliferation and EMT process. 
We also used rescue experiments to confirm the effect of miR-484 on CC cells through directly regulating the expres-
sion of its targets.
Results: Firstly we found miR-484 was down-regulated in cervical cancer tissues and cell lines compared with their 
matched non-cancerous tissues or normal cervical keratinocytes cells. Further studies revealed that overexpres-
sion of miR-484 suppressed the cell proliferation, while exacerbates apoptosis. Besides, miR-484 suppressed cellular 
migration, invasion and EMT process of CC cells. EGFP reporter assay showed that miR-484 binds to ZEB1 and SMAD2 
3′UTR region and reduced their expression. The expression of miR-484 had reverse correlation with SMAD2/ZEB1, 
and SMAD2/ZEB1 had positive correlation with each other in cervical cancer tissues and cell lines. Furthermore, the 
ectopic expression of ZEB1 or SMAD2 could rescue the malignancies suppressed by miR-484, suggesting that miR-
484 down-regulates ZEB1 and SMAD2 to repress tumorigenic activities.
Conclusion: We found miR-484 inhibits cell proliferation and the EMT process by targeting both ZEB1 and SMAD2 
genes and functions as a tumor suppressor, which may served as potential biomarkers for cervical cancer.
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Background
Cervical cancer (CC) is the fourth leading cause among 
cancer-related deaths in women, and due to delayed ini-
tial screening, it mainly occurs in developing countries 
and causes about 265,000 deaths every year worldwide 
[1]. Nowadays, advances in CC therapies have improved 
treatment outcomes, while the prognosis remains lim-
ited and ineffective and a great number of patients died 
of metastasis. Although human papilloma virus (HPV) 
is the major risk factor for CC [2, 3], independent altera-
tions in tumour suppressor genes and oncogenes are 
essential for the development of these cancers as well [4, 
5]. Therefore, it’s crucial to identify specific molecules 
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and markers that contribute to understanding cervical 
carcinogenesis and ascertaining diagnostic and treatment 
strategies. Recently, researchers have focused on the 
effect of miRNAs on CC and a lot of miRNAs were found 
to play great importance in the initiation and develop-
ment of CC [6–8].
MicroRNAs are a class of 18-25-nucleotide, highly 
conserved non-coding RNAs that post-transcriptionally 
regulate gene expression by binding to their 3′UTRs and 
regulate a wide range of physiological and pathologi-
cal processes including cell differentiation, proliferation, 
apoptosis, invasion and migration [9–12]. In addition, 
growing evidences indicate that miRNAs are aberrantly 
expressed in human cancers and may function as tumor 
suppressors or oncogenes [13]. miR-484 was located on 
chr6. The expressions and functions of miR-484 in cancers 
were little. Although Yang et al. [14] reported that miR-484 
was overexpressed in premalignant lesions of hepatocellu-
lar carcinoma (HCC), and can promote hepatocyte trans-
formation and hepatoma development in two hepatocyte 
orthotopic transplantation models. Until now, the role and 
mechanism of miR-484 in CC cells are not clear.
Epithelial–mesenchymal transition (EMT) is an essen-
tial requirement for cancer invasion and metastasis 
[15–17]. The transcription factors Snail, Slug, Twist, 
zinc finger E-box-binding homeobox (ZEB) play vital 
role in initiation of EMT process. Recent reports have 
showed that the miR-200 family and other miRNAs regu-
late EMT through targeting these transcription factors 
[18–20]. ZEB family factors (ZEB1 and ZEB2) are tran-
scriptional repressors that comprise two widely separated 
clusters of C2H2-type zinc fingers which bind to paired 
CAGGTA/G E-box-like promoter elements. These fac-
tors promote EMT by repressing expression E-cadherin 
[21–23] and are important intracellular mediators of 
TGFβ-induced EMT. Over the past few years, ZEB1 has 
increasingly been considered as an important contributor 
to the process of malignancies including endometrioid 
cancer [24], breast cancer [25], lung adenocarcinomas 
[26] as well as cervical cancer [27]. On the one hand, 
it has been shown that miRNAs, such as the miR-200 
family can directly bind to 3′UTR of the ZEB mRNA to 
down-regulate its expression and influence epithelial 
differentiation [28, 29]. On the other hand, it has been 
revealed that SMAD proteins directly act with the pro-
moter of the ZEB factor and indirectly regulates estab-
lishment and maintenance of EMT [30, 31].
In this report, we demonstrated that miR-484 is down-
regulated in cervical cancer tissues and cell lines, and 
overexpression of miR-484 inhibits cell proliferation, 
cell viability and exacerbates apoptosis, suppresses cell 
migration, invasion and EMT process of CC cells as well. 
Moreover, miR-484 was validated to directly bind to the 
3′UTR of the ZEB1 and SMAD2 transcript, inhibiting 
their expression in CC cells. We also found that SMAD2 
is an upstream regulator of ZEB1. Therefore, miR-484 
regulated EMT process through both directly and indi-
rectly targeting ZEB1. Collectively, our present work 
provides the first evidence that miR-484 down-regulates 
ZEB1 and SMAD2 expression to repress malignant prop-
erties in CC cells. The findings may provide insights into 
the mechanisms underlying carcinogenesis and potential 
biomarkers for cervical cancer.
Methods
Human cervical cancer tissue specimens and cell lines
Fifteen CC tissues and the paired adjacent non-tumor 
cervical tissues were obtained from the cancer center 
of Sun Yat-sen University. The diagnose was evaluated 
by pathological analysis. Written informed consent was 
obtained from each patient and ethics approval for this 
work was granted by the Ethics Committee of Sun Yat-
Sen University. The cervical samples were classified by 
pathologists. The human CC cell lines HeLa, Caski and 
ME-180 were maintained in RPMI-1640 medium. C33A, 
SiHa and SW756 were maintained in MEM-α medium 
according to Ref. [32]. Primary cultures of normal cer-
vical keratinocytes (NCx) were obtained from hyster-
ectomy specimens removed for non-neoplastic disease 
unrelated to the cervix. Cell culture and determination 
of growth rates were according to Ref. [33]. All the cells 
were maintained in a humidified incubator with 5% car-
bon dioxide (CO2) at 37 °C.
Vector construction
To over-express miR-484, the primary miR-484 frag-
ment was amplified from genomic DNA and cloned into 
pcDNA3 vector between BamHI and EcoRI sites. To block 
the function of miR-484, we purchased the 2′-O-methyl-
modified antisense oligonucleotide of miR-484 (ASO-
miR-484) and the scramble control oligonucleotides 
(ASO-NC) from the GenePharma (Shanghai, China).
The gene encoding ZEB1/SMAD2 was amplified from 
the cDNA of HeLa cells, and the product was cloned 
into pcDNA3-Flag vector between EcoRI and XhoI sites. 
The shRNA for knocking down SMAD2 and ZEB1 were 
synthesized from GenePharma (Shanghai, China) and 
were annealed and cloned into pSilencer 2.1-neo vector 
(Ambion) between BamHI and HindIII sites.
The 3′UTR of ZEB1/SMAD2 (containing the predicted 
binding sites for miR-484) was amplified from the cDNA 
of HeLa cells and then was cloned into pcDNA3-EGFP 
vector between the BamHI and EcoRI sites (downstream 
of EGFP). The mutant 3′UTR of ZEB1/SMAD2 (five 
nucleotides were mutated in the miR-484 binding sites) 
was amplified from the construct (pcDNA3-EGFP/ZEB1 
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or pcDNA3-EGFP/SMAD2 3′UTR). All of the primers 
for PCR amplification and all the oligonucleotides for 
annealing are listed in Table 1.
Prediction of miRNA targets
miR-484 predicted targets were retrieved from TargetScan 
(http://genes.mit.edu/tscan/targetscanS.html), miRecords 
(http://c1.accurascience.com/miRecords/) and PITA 
(https://genie.weizmann.ac.il/pubs/mir07/) and the bind-
ing site predictions were performed using RNAhybrid 
(http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/).
Cell transfection
Transient transfection was performed in antibiotic-free 
Opti-MEM medium (Invitrogen) with the Lipofectamine 
2000 reagent (Invitrogen, Carlsbad, CA) following the 
manufacturer’s protocol.
RNA isolation and reverse transcription quantity (RT‑qPCR)
Extraction of total RNA from cells was performed using 
the TRIzol reagent (Invitrogen, CA) following the manu-
facturer’s instructions. Expression of mature miRNAs 
and mRNAs were quantified by RT-qPCR using the SYBR 
Premix Ex TaqTM (Promega, Madison, WI). The concen-
tration of RNA were measured with a NanoDrop 2000 
spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA, USA) and stored at −80  °C for further use. Special 
stem-loop primers were used for the miRNA reverse tran-
scription (RT) reaction, and U6 small nuclear B noncoding 
RNA (RNU6B) was used as the endogenous control to nor-
malize the level of miRNA. The oligo (dT) primer was used 
for the RT reaction for gene expression. β-actin was used as 
the endogenous control to normalize the level of genes. All 
analyses were performed in triplicate and reported as 2−
ΔΔCt. The primers for RT and PCR are provided in Table 1.
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Fluorescent reporter assays
To identify the direct target relationship between miR-
484 and the 3′UTR of ZEB1/SMAD2 mRNA, the CC cells 
were cotransfected with pcDNA3/pri-miR-484 or ASO-
miR-484 and the 3′UTR of ZEB1/SMAD2 or the mutant 
3′UTR of ZEB1/SMAD2 in 48-well plates. The vector 
pDsRed2-N1 (Clontech, Mountain View, CA) expressing 
RFP (red fluorescent protein) was transfected together 
with the above plasmids and used as an internal control 
standard. 48 h after transfection, the cells were lysed by 
RIPA buffer and fluorescence intensities of EGFP and 
RFP were detected with an F-4500 fluorescence spectro-
photometer (Hitachi, Tokyo, Japan).
Cell viability assay and colony formation assay
The cell viability of CC cells was evaluated by the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium 
bromide (MTT) assay. The absorbance was determined 
at 570  nm (A570) (Bio-Tek Instruments, Winooski, VT, 
USA) after CC cells transfection for 24, 48 and 72 h. The 
details of methods were according to Ref. [34].
For colony formation assay, the cells were seeded into 
12-well plates at a density of 300 HeLa or 400 C33A per 
well at post-transfection 24  h. Change medium every 
3  days. After 11 or 13  days, the cells were stained with 
crystal violet, and colonies including more than 50 cells 
were counted. The average number was used to evaluate 
the formation ability.
Cell cycle analysis and apoptosis assay by flow cytometry
Cell cycle analysis and apoptosis assay was according to 
Refs. [6] and [35] respectively.
Cell migration and invasion assays
The migration and invasion were analyzed by 24-well 
Boyden chambers with an 8-μm pore size polycarbon-
ate membrane (Corning, Cambridge, MA). Briefly, 
8  ×  105 cells were resuspended in culture medium 
without FBS and seeded in the upper chamber. Then 
the chamber was placed into a 24-well plate containing 
800 μL of culture media with 20% FBS. Approximately 
48  h later, the cells were fixed with paraformaldehyde 
and stained with crystal violet. The cells did not pass 
through the membrane were removed with the cotton 
stick while the cells that passed through the membrane 
were counted.
Western blot analysis
The detailed procedures for western blot were described 
in a previous study [36]. The primary anti-bodies used in 
this study including ZEB1, SMAD2, E-cadherin, cytoker-
atin, vimentin, N-cadherin, fibronectin and GAPDH, 
which were obtained from Saier Co. (Tianjin, China). The 
secondary goat anti-rabbit antibodies were purchased 
from Sigma.
Immunohistochemistry
The tumor tissues were fixed in 4% formaldehyde 
for 24  h and sent to Tangshan People’s Hospital for 
immunohistochemistry.
Statistical analyses
All the data are presented as the mean  ±  SD. Each 
experiment was performed at least three times, and the 
analysis was performed using paired t test. p ≤ 0.05 was 
considered statistically significant (*p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001).
Results
miR‑484 is down‑regulated in cervical cancer tissues
We first examined the expression of miR-484 in 15 pairs 
of cervical cancer tissues and the adjacent noncancer-
ous tissues by RT-qPCR. The results showed that miR-
484 was generally down-regulated in cervical cancer 
tissues compared with the adjacent noncancerous tissues 
(Fig. 1a).
miR‑484 inhibits cell growth of cervical cancer cells, 
suppresses cell cycle while exacerbates apoptosis 
in cervical cancer cells
First, we tested the efficiency of the plasmids pcDNA3/
pri-miR-484 and ASO-miR-484 in HeLa and C33A cells 
with RT-qPCR. The results showed that both the plas-
mid and ASO-miR-484 can change the miR-484 expres-
sion efficiently (Fig.  1b). Next, MTT assays were used 
to test cell viability after transfecting with pcDNA3/
pri-miR-484 or ASO-miR-484 at 24, 48 and 72  h. The 
results showed that miR-484 decreased, whereas ASO-
miR-484 increased cell viability in both HeLa and C33A 
cells (Fig.  1c). Meanwhile, colony formation assay was 
performed to test the effects of miR-484 on proliferation. 
The results showed that the overexpression of miR-484 
suppressed, whereas ASO-miR-484 increased the colony 
formation rate (Fig.  1d). Taken together, these results 
indicate that miR-484 suppresses the proliferation of 
HeLa and C33A cells.
To investigate the mechanisms underlying the regula-
tion of cell growth, we examined the alterations in cell 
cycle progression and apoptosis caused by miR-484 in 
the HeLa cells using flow cytometry analysis. As shown 
in Fig.  2a, the overexpression of miR-484 in HeLa cells 
increased the percentage of cells in the G1 phase from 
66.69 to 75.00% and decreased the percentage of cells in 
the G2/M phase from 13.8 to 7.87% (Fig.  2b). The pro-
liferation index of the miR-484-treated cells was appar-
ently lower than that of the negative control (Fig. 2b). In 
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contrast, inhibition of miR-484 by antisense oligonucleo-
tides in HeLa cells led to an increase in the percentage 
of cells in the G2/M phase from 13.85 to 21.90% and a 
decrease in the percentage of cells in the G1 phase from 
65.32 to 56.87% (Fig. 2b). The proliferation index of the 
ASO-miR-484-treated HeLa cells was increased com-
pared with the ASO control (Fig.  2b). In addition, flow 
cytometry results showed that miR-484 exacerbates 
apoptosis, while ASO-miR-484 inhibited apoptosis obvi-
ously in CC cells (Fig. 2c). Taken together, all these results 
indicated that miR-484 suppresses cell growth by both 
delaying the G1 to S phase and the S to G2 phase transi-
tions and exacerbating apoptosis in CC cells.
miR‑484 suppresses the migration and invasion of cervical 
cancer cells and inhibits the EMT process
To explore the effects of miR-484 on the migration and 
invasion of CC cells transwell migration and invasion 
assays were performed. The transwell membrane was 
coated with Matrigel in the invasion assay. The results 
Fig. 1 miR-484 suppresses the proliferation of CC cells. a RT-qPCR showed the expression of miR-484 in 15 pairs of human cervical cancer tissues 
and the adjacent noncancerous tissues. U6 snRNA was used as the internal control. b After transfection 48 h, RT-qPCR was performed to detect miR-
484 levels in HeLa or C33A cells transfected with pcDNA3/pri-miR-484 or ASO-miR-484. c After transfection 24, 48, 72 h, MTT assay was performed 
to measure cell viability in HeLa or C33A cells transfected with pcDNA3/pri-miR-484 or ASO-miR-484. d Colony formation assay was performed to 
determine the effect of miR-484 on the long-term proliferative activity of HeLa or C33A cells. The control was normalized to 1
Page 6 of 17Hu et al. Cancer Cell Int  (2017) 17:36 
Fig. 2 miR-484 suppresses cell cycle of CC cells and exacerbates apoptosis. a, b The cell cycle progression of HeLa cells was analyzed by flow 
cytometry. The chart shows the population of cells in G1-, S- and G2-phase (a) as well as the proliferation index (b). Proliferation index = (S + G2)/
G1 (S, G2 and G1 are the percentages of cells in S-phase, G2-phase and G1-phase, respectively). c After transfection 24 h, apoptosis of HeLa cells 
was monitored by Annexin V-PI double staining and flow cytometry assay. Paclitaxel was used to induce cell apoptosis 6 h before collecting cells. 
The right lower quadrant of each plot contains early apoptotic cells, whereas the right upper quadrant contains late apoptotic cells. All data represent 
mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001
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showed that overexpression of miR-484 significantly sup-
pressed the migration ability by approximately 59.8 and 
43.7% in HeLa and C33A cells; while blocking of miR-484 
increased the migration ability by approximately 1.7- and 
1.9-fold in HeLa and C33A cells respectively (Fig. 3a). The 
overexpression of miR-484 suppressed the invasion ability 
by approximately 52.1 and 44% in HeLa and C33A cells; 
while ASO-miR-484 increased the invasion ability by 1.6- 
and 1.7-fold in HeLa and C33A cells respectively (Fig. 3b).
It has been reported that EMT is an important mecha-
nism correlated with migration and invasion [22]. During 
the transition, the expression of epithelial markers that 
enhance cell–cell contact decreases, while the expres-
sion of mesenchymal markers increases [17]. Therefore, 
we tested the expression of molecular markers to clarify 
the effects of miR-484 on the EMT process. As shown 
in Fig. 3c, the overexpression of miR-484 increased epi-
thelial markers (E-cadherin and cytokeratin) protein 
levels but decreased mesenchymal markers protein lev-
els (vimentin, N-cadherin and fibronectin) in both HeLa 
and C33A cells. By contrast, ASO-miR-484 decreased the 
epithelial markers but increased the mesenchymal mark-
ers protein levels. Importantly, RT-qPCR showed that 
miR-484 decreased the expression of transcription fac-
tors Snail, Slug, Twist and ZEB1 which play vital role in 
initiation of EMT process (Fig. 3d). With the modulation 
of miR-484, the expression of ZEB1 showed the great-
est alteration. In summary, these results demonstrated 
that miR-484 suppresses the migration and invasion and 
inhibits the EMT process of CC cells.
miR‑484 targets and down regulates ZEB1 and SMAD2 
expression
As miR-484 suppresses cervical cancer cell growth, 
migration, and invasion, it is important to understand 
which targets are directly responsible for the observed 
phenotypes. We used three prediction algorithms (Tar-
getScan, miRecords, and PITA) to predict the targets for 
miR-484 in common. There were 258 candidate targets 
shared by all the three databases (the overlapping frac-
tion), in which only four genes involved in the regulation 
of EMT process (Fig. 4a). Based on our data (Fig. 3d) and 
previous reports, we chose ZEB1 and SMAD2 for fur-
ther study. ZEB1 usually acts as a key transcription factor 
which can induce EMT, and our data had shown ZEB1 
expression was altered with the modulation of miR-484 
(Fig. 3d), which suggested that ZEB1 may be a bona fide 
target of miR-484. Moreover, the previous work in our 
lab has demonstrated that SMAD2 promotes cell growth, 
migration, invasion, and EMT in Human CC Cell Lines 
[6]. Other reports have revealed that Smads interact with 
the ZEB promoter [30, 31]. Therefore, we chose SMAD2 
as a second candidate target of miR-484.
To confirm whether SMAD2 and ZEB1 are direct tar-
gets of miR-484 in human CC cells, we used an EGFP 
reporter system, in which we cloned the wild SMAD2/
ZEB1 3′-UTR or a mutant SMAD2/ZEB1 3′-UTR 
downstream of the EGFP reporter gene (Fig.  4b). Co-
transfection was performed with an RFP reporter as a 
transfection normalizer and with either pri-miR-484 or 
ASO-miR-484 in HeLa cells. After 48 h, we determined 
the fluorescence intensity. As shown in Fig.  4c, overex-
pression of miR-484 decreased the fluorescent intensity 
of the wild type ZEB1/SMAD2 3′UTR. In contrast, ASO-
miR-484 increased the fluorescent intensity (Fig.  4c). 
However, neither the over-expression nor inhibition of 
miR-484 affected the fluorescent intensity of the mutant 
ZEB1/SMAD2 3′UTR (Fig. 4c).
We also explored the functions of miR-484 in the 
expression of endogenous ZEB1/SMAD2 protein by 
western blot. The results showed that the overexpression 
of miR-484 decreased, while ASO-miR-484 increased the 
expression of ZEB1/SMAD2 (Fig.  4d). Thus, the results 
demonstrate that miR-484 directly targets the 3′UTR of 
ZEB1/SMAD2 and down-regulates their protein expres-
sions in CC cells.
Interestingly, we observed that overexpression of 
SMAD2 led to an increase in ZEB1 protein level (Fig. 4e). 
Conversely, decreased SMAD2 prevented up-regulation 
of ZEB1 protein level. This indicates that SMAD2 is an 
upstream regulator of ZEB1 and regulated its expression. 
These results demonstrate that miR-484 directly targets 
the 3′UTR of ZEB1 and SMAD2 mRNA and down-regu-
lates their expression simultaneously.
ZEB1 and SMAD2 rescue the suppression of the malignant 
behavior induced by miR‑484
Based on our results, we questioned whether the effect of 
miR-484 on CC cells is mediated by its down-regulatory 
effect on SMAD2 and ZEB1 expression. We performed 
rescue experiments to address this issue. First, we co-trans-
fected miR-484 with the SMAD2/ZEB1 expression plasmid 
without the 3′UTR which has been proved worked (Fig. 5a) 
and confirmed the over-expression of SMAD2/ZEB1 could 
rescue the decrease in SMAD2/ZEB1 protein levels caused 
by miR-484 (Fig. 5a). Then we performed a series of func-
tional rescue experiments. As expected, the restoration of 
SMAD2/ZEB1 expression mostly blocked the inhibitory 
effects of miR-484 on the cell viability (Fig. 5b), colony for-
mation rate (Fig. 5c) and cell cycle (Fig. 6a). SMAD2/ZEB1 
also restored the apoptosis induced by miR-484 (Fig.  6b). 
In addition, the restoration of SMAD2/ZEB1 can also 
counteract the suppression of the migration/invasion via 
miR-484 (Fig. 7a, b). Meanwhile, the ectopic expression of 
SMAD2/ZEB1 counteracts the inhibition of EMT induced 
by miR-484 in CC cells (Fig. 7c).
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To confirm the deduce that the effect of miR-484 on CC 
cells is mediated by its down-regulatory effect on SMAD2 
and ZEB1 expression in an inverse way, ASO-miR-484 
along with pshR-ZEB1/SMAD2 was co-transfected 
into HeLa and C33A cells. As anticipated, the effects 
of miR-484 blocking on cell growth were significantly 
impaired when ZEB1/SMAD2 was suppressed (Fig.  8a, 
b). Furthermore, the expressions of EMT markers in the 
(See figure on previous page.) 
Fig. 3 miR-484 suppresses the migration and invasion of CC cells and down-regulates the EMT process. a, b After transfection 48 h, cell migration 
(a) and invasion (b) were evaluated using a transwell system with 8 μm pores in polycarbonate membranes. Representative views of migratory or 
invasive cells on the membrane were presented below. All pictures were photographed at ×20 magnification. c Protein levels of EMT-associated 
markers were assessed by western blotting after transfection 48 h. d RT-qPCR analysis for the expression of EMT transcription factors ZEB1, Snail, 
Slug and Twist2 in HeLa cells transfected with miR-484 or the control vector. The control was normalized to 1. All data represent mean ± SD of three 
independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 4 miR-484 directly targets SMAD2/ZEB1 and down-regulates their expressions. a The venn diagram shows the potential target genes (overlap-
ping fraction) that were shared by all three databases. b The predicted binding sites for miR-484 in the 3′UTR of SMAD2 and ZEB1 and the mutations 
in the binding sites are shown. c The EGFP reporter assay was performed in HeLa or C33A cells co-transfected with pcDNA3/EGFP-SMAD2/ZEB1 
3′UTR wild type or pcDNA3/EGFP-SMAD2/ZEB1 3′UTRmut with pri-miR-484 or ASO-miR-484. The fluorescence intensities were measured at 48 h 
after transfection. d Western blot assays were used to detect the SMAD2 and ZEB1 protein levels in HeLa or C33A cells transfected with pcDNA3/
pri-miR-484, ASO-miR-484 or their corresponding controls. e Western blot assays tested the effect of SMAD2 on the expression of ZEB1. *p < 0.05, 
**p < 0.01, ***p < 0.001, ns, no significance. All the bars indicate the means ± SDs. All experiments were performed at least triplicates
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miR-484-blocking cells were restored to the normal lev-
els after knocking-down of ZEB1/SMAD2 (Fig.  8c). In 
conclusion, all these data indicate that SMAD2 and ZEB1 
are functional targets of miR-484 in cervical cancer cells.
miR‑484 is inversely correlated with SMAD2 and ZEB1 
expressions in cervical cancer tissues and cell lines
To further explore the expression levels of ZEB1 and 
SMAD2 in cervical cancer, we performed RT-qPCR 
analyses to examine their expression levels in 15 pairs 
of CC tissues and adjacent non-tumor tissues as well 
as a panel of cervical cancer cell lines. We found that 
ZEB1 and SMAD2 were both upregulated in cancer tis-
sues compared with the adjacent non-tumor tissues, 
which was opposite to the expression pattern of miR-484 
(Fig. 9a). By Pearson’s correlation analysis, miR-484 pre-
sented a reverse correlation with the expression of ZEB1 
(r  =  −0.70, p  <  0.01) and SMAD2 mRNA (r  =  −0.65, 
p  <  0.001) (Fig.  9b). Interestly, the expression of ZEB1 
and SMAD2 presented a positive correlation (r =  0.61, 
Fig. 5 The ectopic expression of SMAD2 and ZEB1 counteracts the inhibition of cell proliferation induced by miR-484. a CC cells were co-trans-
fected with pcDNA3/pri-miR-484 and pFlag-SMAD2/ZEB1 without its 3′UTR or the control vector and western bolt assay was used to determine the 
restoration of SMAD2 or ZEB1 protein levels by pFlag-SMAD2/ZEB1 in the presence of miR-484. b After transfection 48 h, MTT assay was performed 
to detect cell viability in CC cells. c The transfected cells were submitted to colony formation assays to test the proliferation of CC cells. All data 
represent mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001
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p  <  0.05) (Fig.  9b). We also performed immunohisto-
chemistry (IHC) to determine the expressions of ZEB1 
and SMAD2 in clinical cervical samples. The results fur-
ther demonstrated that ZEB1 and SMAD2 were both 
upregulated in cervical cancer tissues compared with the 
normal cervix (Fig. 9e).
We also determined the expressions of miR-484, ZEB1 
and SMAD2 using RT-qPCR and western blotting analy-
ses in a panel of cervical cancer cell lines as well as nor-
mal cervical keratinocytes cells. RT-qPCR and western 
blotting analyses revealed a significant inverse correla-
tion between miR-484 and ZEB1/SMAD2 expression 
levels in different cervical cancer cell lines (Fig.  9c, d). 
The expression of ZEB1/SMAD2 in HeLa cells changed 
the most sharply while in C33A cells changed the least 
sharply compared with others. The expression of miR-
484 and SMAD2/ZEB1 in both the tissues and cell lines 
indicated that miR-484 had reverse correlation with 
SMAD2/ZEB1, and that SMAD2 and ZEB1 had positive 
correlation with each other.
In conclusion, miR-484 regulated cell proliferation 
and EMT process through both directly and indirectly 
targeting ZEB1. As shown in Fig.  9e, we illustrated the 
regulation network reported by this work. To our notice, 
Fig. 6 The ectopic expression of SMAD2 and ZEB1 counteracts the inhibition of cell cycle and the promotion of apoptosis induced by miR-484. 
a The cell cycle progression of HeLa cells was analyzed by flow cytometry. b After transfection 24 h, apoptosis of HeLa cells was monitored by 
Annexin V-PI double staining and flow cytometry analysis. All data represent mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, 
***p < 0.001
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ZEB1 was the central molecules in this regulatory path-
way. On one hand, miR-484 could inhibit cell prolifera-
tion and EMT process by directly targeting ZEB1. On the 
other hand, miR-484 suppresses cell growth and EMT 
by directly targeting SMAD2, an important upstream 
regulator of ZEB1 (Fig.  10). These results indicate that 
miR-484 exerts multiple pathways of regulation on ZEB1 
expression resulting in the inhibition of cell growth and 
EMT.
Discussion
miRNAs have been indicated to be important regulators 
of a variety of biological processes, and their aberrant 
expressions are relevant to cancer initiation and develop-
ment. In recent years, miRNAs were reported as poten-
tial biomarkers as therapeutic approaches in human 
cancers [37]. Understanding the role of miRNAs in cer-
vical cancer will provide theoretical basis for miRNA-
specific personalized treatment and molecular-targeted 
therapy.
miR-484 was originally discovered to be associated 
with resistance to chemotherapeutic agents in cancer 
[38]. This year, an aberrant expression of miR-484 has 
also been described in high-fat-diet-induced tumours, 
with a fluctuant miR-484 overexpression during feeding 
[39]. Ectopic expression of miR-484 initiates tumourigen-
esis and cell malignant transformation of HCC through 
synergistic activation of the TGF-β/Gli and NF-κB/IFN-I 
pathways [14]. This indicated that miR-484 may act as 
a significant role in tumor metastasis including EMT 
process. To our understanding, the functional study 
of miR-484 in cervical cancer is still missing. Here, we 
demonstrated that miR-484 was down-regulated in cer-
vical cancer tissues compared to adjacent non-tumor 
tissues, which is different from the result in HCC. These 
differences may be due to the different types of cancer 
and the phases of the cancer, but the mechanisms need 
to be elucidated in the future. For example, miR-200s is 
downregulated and inhibit local invasion in breast can-
cer but enhances spontaneous metastasis and coloniza-
tion of lung adenocarcinoma [40]. Functional analyses 
revealed that overexpression of miR-484 suppressed 
the malignant behavior of cervical cancer cells. Specifi-
cally, miR-484 overexpression significantly inhibited the 
cell proliferation, migration, invasion and EMT, whereas 
ASO-miR-484 enhanced these oncogenic features. In 
addition, western blot indicated that the expression of 
EMT markers including E-cadherin, cytokeratin, vimen-
tin, N-cadherin and fibronectin were significantly modu-
lated by miR-484, which is consistent with the formation 
Fig. 8 Knockdown of SMAD2/ZEB1 abrogates the effects induced 
by ASO-miR-484. a After co-transfection with ASO-miR-484 and 
pshR-SMAD2/ZEB1 or the control vector for 48 h, MTT assay was 
performed to detect cell viability in CC cells. b The transfected cells 
were submitted to colony formation assays to test the proliferation of 
CC cells. c The expression of EMT markers (E-cadherin and vimentin) 
was detected by western blot analysis. All data represent mean ± SD 
of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001
(See figure on previous page.) 
Fig. 7 The ectopic expression of SMAD2 and ZEB1 counteracts the inhibition of migration, invasion and EMT progression induced by miR-484. a, b 
Transwell migration/invasion assays and three-dimensional Matrigel culture to test the cells’ abilities to migration (a) and invasion (b). c Protein lev-
els of EMT-associated markers were assessed by western blotting after transfection for 48 h. *p < 0.05, **p < 0.01, ***p < 0.001. All the bars indicate 
the means ± SDs. All experiments were repeated at least three times
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Fig. 9 The inverse correlation between the expression of miR-484 and ZEB1/SMAD2 in cervical cancer tissues and cell lines. a RT-qPCR showing 
the expression of SMAD2 and ZEB1 in 15 pairs of human cervical cancer tissues and the adjacent noncancerous tissues. U6 snRNA was used as the 
internal control. b Pearson’s correlation analysis indicated the negative correlation between the expression of miR-484 and ZEB1 (r = −0.55*) and 
SMAD2 (r = −0.65***). c RT-qPCR showing the expression of miR-484, SMAD2 and ZEB1 in cervical cancer cell lines compared with NCx. U6 snRNA 
and β-actin were used as the internal controls. d Western blot were used to detect the ZEB1 and SMAD2 protein levels in cervical cancer cell lines 
compared with NCx. All data represent mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. e Repre-
sentative IHC images showing the expression level of SMAD2 and ZEB1 in cervical cancer and normal cervix (×20)
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Fig. 10 Schematic that describes the role of miR-484 in CC cells. miR-
484 regulated proliferation and EMT process through both directly 
and indirectly targeting ZEB1 in CC cells
of EMT. Collectively, miR-484 functions as a tumor sup-
pressor in cervical cancer cells.
miRNAs generally play their roles by regulating their 
target genes. To better understanding the role of miR-484 
in CC, we applied bioinformatics analyses to predict that 
the 3′UTR of SMAD2/ZEB1 contains miR-484 binding 
sites. EGFP reporter assay demonstrated that miR-484 
directly targets SMAD2 and ZEB1 transcripts. Western 
blot analyses showed the decreased expression of ZEB1 
and SMAD2 upon overexpression of miR-484 and vise 
versa. Functionally, overexpression of miR-484 could 
inhibit cell proliferation, migration, invasion and EMT, 
while the ectopic expression of SMAD2/ZEB1 abrogated 
the inhibitory effects of miR-484 on these tumorigenic 
features in cervical cancer cells. Meanwhile, we also 
showed that knocking-down of SMAD2/ZEB1 abrogated 
the tumorigenic effects induced by ASO-miR-484. Thus, 
we concluded that miR-484 may function as tumor sup-
pressor by down-regulation of ZEB1 and SMAD2 expres-
sions in cervical cancer.
Upregulation of the expression of ZEB1 plays an 
important role in the progression and metastasis in many 
cancers [24–26], including cervical cancer [27]. Our pre-
vious study has shown that SMAD2 promotes cell growth 
by facilitating the G1/S phase transition, enhances cell 
migration and invasion through regulated EMT in CC 
cell lines [6]. In addition, regulating SMAD2 by miRNAs 
has been identified to be involved in the TGFβ-induced 
EMT. For example, miR-18b targets SMAD2 and inhibits 
TGF-β1-induced differentiation of hair follicle stem cells 
into smooth muscle cells [41], and miR-27a inhibits colo-
rectal carcinogenesis and progression [42]. Expectedly, 
ectopic expression of SMAD2 counteracts the inhibi-
tion of EMT induced by miR-484 in CC cells. The resto-
ration of SMAD2/ZEB1 expression mostly blocked the 
inhibitory influence of miR-484 on malignant behavior 
(Figs.  5, 6, 7). The expression of miR-484 and SMAD2/
ZEB1 in the tissues and cell lines demonstrated that 
miR-484 had negative correlation with SMAD2/ZEB1, 
and that SMAD2 had positive correlation with ZEB1 
(Fig.  9b, c). This result further supported that SMAD2 
is an upstream protein of ZEB1 and they are both regu-
lated by miR-484. Previous work has demonstrated that 
SMAD directly binds to the promoter of the ZEB factor 
and indirectly regulates EMT [30, 31], which is in accord-
ance with our results in CC. In summary, all these results 
prove that miR-484 inhibits the development of CC and 
may partially (if not completely) through down-regulat-
ing SMAD2 and ZEB1 expressions.
Except for ZEB, other transcription factors such as 
Snail, Slug and Twist are also the master regulators of 
EMT [22], which can activated by TGFβ directly and 
repress the transcription of E-cadherin [23]. The TGFβ/
ZEB/miR-200 double-negative feedback loop has been 
found and postulated to explain both the stability and 
interchangeability of the epithelial versus mesenchymal 
phenotypes in MDCK cell systems [43, 44]. In the present 
study, we found that miR-484 could target both SMAD2 
and ZEB1 genes simultaneously, and ZEB1 is regulated 
by SMAD2 as well, which is different from The ZEB/
miR-200 double-negative feedback loop. Interesting, our 
results also showed that miR-484 affects the expression 
of Snail, Slug and Twist as well, which may due to miR-
484 regulating ZEB1 to the EMT-related regulators, while 
the detailed regulatory mechanism need to be further 
investigated. These results indicate that miR-484 exerts 
multiple pathways of regulation on EMT and highlight 
the importance of stringently regulating transcription 
factors. These findings also fit the emerging concept that 
miRNAs fine-tune gene expression to precisely modulate 
essential biological processes and provide a mechanistic 
view of miRNA-based regulation on specific molecules 
and markers involved in cancer metastasis.
Despite these studies, further development of the 
underlying mechanisms need to be investigated. And our 
next work is to found out the upstream regulatory mech-
anisms of miR-484 in CC cells.
Conclusions
In summary, our study demonstrated that miR-484 plays 
an important role in tumorigenesis and related to the 
EMT process in CC for the first time. miR-484 inhibits 
the proliferation, and exacerbates apoptosis, suppresses 
migration, invasion and EMT process through the 
down-regulation of ZEB1 and SMAD2 expression and 
functions as a tumor suppressor gene. In other words, 
miR-484 regulated EMT process through both directly 
and indirectly targeting ZEB1. Altogether, our findings 
provide new insights into the roles of miR-484 in cervical 
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carcinogenesis and imply its potential applications as 
new biomarkers in cervical cancer.
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